221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1653
Enrollment
INDUSTRY
Sponsor class

Stopped Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed

Conditions

Interventions

Sponsor

Biogen